Mylan (MYL) has introduced a generic version of its EpiPens after public outrage over its pricing. But TheStreet's Jim Cramer says he's happy the company rolled back prices, but he still isn't a fan of the stock.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.